Have you been prescribed BLENREP for your relapsed multiple myeloma?
Myeloma is a relapsing, remitting cancer and we understand that starting a new treatment can come with a number of questions. This website is designed to help you understand more about your BLENREP medication and appointments. If you still have any questions, we recommend you ask your cancer care team.
If you experience any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or uksafety@gsk.com.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See information in paragraph above to see how to report side effects.
BLENREP is a registered trademark of the GlaxoSmithKline group of companies
